Medicis declares Notice of Allowance for SOLODYN 90mg from USPTO
MRX | Quote | Chart | News | PowerRating -- Medicis (NYSE:MRX), an independent speciality pharmaceutical company,
reported on 3 April the issuance of a Notice of Allowance from the US
Patent and Trademark Office (USPTO) for the company's United States
patent application regarding the use of SOLODYN in 90mg tablet form.
The 90mg strength represented over 60% of total SOLODYN prescriptions
for the week ending 20 March 2009.
The company stated that the patent application is US Application No.
11/695,528, entitled 'Minocycline Oral Dosage Forms For The Treatment
Of Acne'. The newly allowed claims include subject matter covering
methods of using a controlled-release oral dosage form of minocycline
to treat acne.
SOLODYN has one issued patent, US patent No. 5,908,838, which expires
in 2018, related to the use of the SOLODYN unique dissolution rate. The
company has a number of US patent applications associated with the
SOLODYN programme on file at the USPTO.
SOLODYN is the only branded oral minocycline approved for once daily
dosage in the treatment of inflammatory lesions of non-nodular moderate
to severe acne vulgaris in patients aged 12 and older.
Comments on this story may be sent to admin@m2.com
For full details on Medicis Pharmaceutical A (MRX) MRX. Medicis Pharmaceutical A (MRX) has Short Term PowerRatings at TradingMarkets. Details on Medicis Pharmaceutical A (MRX) Short Term PowerRatings is available at This Link.
- Zacks Analyst Blog Highlights: MasterCard Incorporated, Broadcom Corporation, Allergan, Inc., Medicis Pharma and Johnson & J - 02/05/10
- Medicis Pharmaceutical: The Trend Continues Lower (MRX) - 02/05/10
- US FDA approsves Q-Med's Restylane Lidocain, Perlane Lidocain - 02/04/10
- Medicis Receives Approval for RESTYLANE(R) and PERLANE(R) With Lidocaine - 02/03/10
- SmarTrend Detects Continued Selling Pressure in Shares of Medicis Pharmaceutical (MRX) - 01/29/10
- More News >>
